JPRN-UMIN000043113招募中未知
Accompanying research No. 2 of "Analyses of immune status in malignant tumor patients": analysis of immune status of the tumor microenvironment in esophageal cancer patients treated with PD-1 blockade therapy - Analysis of immune status of the tumor microenvironment in esophageal cancer patients treated with PD-1 blockade therapy
Chiba Cancer Center0 个研究点目标入组 20 人开始时间: 2021年1月25日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Clinicians judge as ineligible cases.
研究者
相似试验
已完成
不适用
An accompanying research for the Phase II study of nivolumab + bevacizumab + paclitaxel in patients with HER2-negative metastatic breast cancer:WJOG9917B(WJOG9917BTR)HER2-negative metastatic breast cancerJPRN-UMIN000029590West Japan Oncology Group51
尚未招募
不适用
Prospective observational study for multiple myeloma (MM) in JapaJPRN-UMIN000046988THE JAPANESE SOCIETY OF HEMATOLOGY1,200
进行中（未招募）
1 期
An extension to a phase II study to determine the safety and anti-leukemic effects of STI571 in patients with Philadelphia chromosome-positive leukemia including acute lymphoblastic leukaemia, acute myeloid leukaemia, and accelerated phase chronic myeloid leukemia - N/AEUCTR2004-001396-19-GBovartis Pharmaceuticals UK Ltd293
进行中（未招募）
不适用
An extension to a phase II study to determine the safety and the anti- leukemic effects of STI571 in adults patients with Philadelphia chromosome positive leukemia including acute lymphoblastic leukemia, acute myeloid leukemia and accelerate phase myeloid leukemia.EUCTR2005-001381-14-ITOVARTIS FARMA294
进行中（未招募）
1 期
An extension to a phase II study to determine the efficacy and safety of STI571 in patients with chronic myeloid leukemia who are refractory to or intolerant of interferon-alpha - N/APhiladelphia chromosome-opositive chronic myeloid leukamia in myeloid blast crisisEUCTR2004-001397-92-GBovartis Pharmaceuticals UK Ltd532